Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer

Journal of Controlled Release

Volumn 129, Issue 2, 2008, Pages 107-116

  Kim, Sun Hwa ^a   Jeong, Ji Hoon ^b   Lee, Soo Hyeon ^a   Kim, Sung Wan ^c,d   Park, Tae Gwan ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c UNIVERSITY OF UTAH   (United States)

^d Hanyang University   (South Korea)

Author keywords

Anti angiogenesis; Polyelectrolyte complex micelles; siRNA delivery; Vascular endothelial growth factor

Indexed keywords

CELL DEATH; COMPLEXATION; GROWTH KINETICS; MICELLES; ONCOLOGY; POLYELECTROLYTES;

ANTI-ANGIOGENESIS; POLYELECTROLYTE COMPLEX MICELLES; SIRNA DELIVERY; VASCULAR ENDOTHELIAL GROWTH FACTOR;

RNA;

POLYELECTROLYTE; SMALL INTERFERING RNA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MICELLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELL LINE, TUMOR; ENDOCYTOSIS; FEASIBILITY STUDIES; FEMALE; GENE THERAPY; HUMANS; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, NUDE; MICELLES; MICROSCOPY, FLUORESCENCE; NEOVASCULARIZATION, PATHOLOGIC; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TIME FACTORS; TISSUE DISTRIBUTION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 46549085779     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.03.008     Document Type: Article

References (53)

1. McManus M.T., and Sharp P.A. Gene silencing in mammals by small interfering RNAs. Nat. Rev., Genet. 3 (2002) 737-747
2. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 (2002) 331-335
3. Dykxhoorn D.M., Novina C.D., and Sharp P.A. Killing the messenger: short RNAs that silence gene expression. Nat. Rev., Mol. Cell Biol. 4 (2003) 457-467
4. Lieberman J., Song E., Lee S.K., and Shankar P. Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol. Med. 9 (2003) 397-403
5. Song E., Lee S.K., Wang J., Ince N., Ouyang N., Min J., et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9 (2003) 347-351
6. Gartel A.L., and Kandel E.S. RNA interference in cancer. Biomol. Eng. 23 (2006) 17-34
7. McNamara J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nature 24 (2006) 1005-1015
8. Takeshita F., Minakuchi Y., Nagahara S., Honma K., Sasaki H., Hirai K., et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 12177-12182
9. Hu-Lieskovan S., Heidel J.D., Bartlett D.W., Davis M.E., and Triche T.J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's Sarcoma. Cancer Res. 65 (2005) 8984-8992
10. Dorsett Y., and Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov. 3 (2004) 318-329
11. Hannon G.J. RNA interference. Nature 418 (2002) 244-251
12. Lu P.Y., Xie F., and Woodle M.C. In vivo application of RNA interference: from functional genomics to therapeutics. Adv. Genet. 54 (2005) 117-142
13. Oishi M., Nagasaki Y., Itaka K., Nishiyama N., and Kataoka K. Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc. 127 (2005) 1624-1625
14. Kim S.H., Mok H., Jeong J.H., Kim S.W., and Park T.G. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug. Chem. 17 (2006) 241-244
15. Kataoka K., Togawa H., Harada A., Yasugi K., Matsumoto T., and Katayose S. Spontaneous formation of polyion complex micelles with narrow distribution from antisense oligonucleotide and cationic block copolymer in physiological saline. Macromolecules 29 (1996) 8556-8557
16. Vinogradov S.V., Bronich T.K., and Kabanov A.V. Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides. Bioconjug. Chem. 9 (1998) 805-812
17. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32 (2004) e149
18. Kim S.H., Jeong J.H., Cho K.C., Kim S.W., and Park T.G. Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine). J. Control. Release 104 (2005) 223-232
19. Harada A., and Kataoka K. Formation of polyion complex micelles in an aqueous milieu from a pair of oppositely-charged block copolymers with poly(ethylene glycol) segments. Macromolecules 28 (1995) 5294-5299
20. Harada-Shiba M., Yamauchi K., Harada A., Takamisawa I., Shimokado K., and Kataoka K. Polyion complex micelles as vectors in gene therapy-pharmacokinetics and in vivo gene transfer. Gene Ther. 9 (2002) 407-414
21. Oishi M., Sasaki S., Nagasaki Y., and Kataoka K. pH-responsive oligodeoxynucleotide (ODN)-poly(ethylene glycol) conjugate through acid-labile beta-thiopropionate linkage: preparation and polyion complex micelle formation. Biomacromolecules 4 (2003) 1426-1432
22. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., and Park T.G. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release 116 (2006) 123-129
23. Jeong J.H., Kim S.W., and Park T.G. A new antisense oligonucleotide delivery system based on self-assembled ODN-PEG hybrid conjugate micelles. J. Control. Release 93 (2003) 183-191
24. Jeong J.H., Kim S.W., and Park T.G. Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide. Bioconjug. Chem. 14 (2003) 473-479
25. Jeong J.H., Kim S.H., Kim S.W., and Park T.G. Polyelectrolyte complex micelles composed of c-raf antisense oligodeoxynucleotide-poly(ethylene glycol) conjugate and poly(ethylenimine): effect of systemic administration on tumor growth. Bioconjug. Chem. 16 (2005) 1034-1037
26. Jackson J.K., Gleave M.E., Yago V., Beraldi E., Hunter W.L., and Burt H.M. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel. Cancer Res. 60 (2000) 4146-4151
27. Cvetkovic D., Movsas B., and Dicker A.P. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 57 (2001) 821-825
28. Kwon H.S., Shin H.C., and Kim J.S. Suppression of vascular endothelial growth factor expression at the transcriptional and post-transcriptional levels. Nucleic Acids Res. 33 (2005) e74
29. Lu P.Y., Xie F.Y., and Woodle M.C. Modulation of angiogenesis with siRNA inhibitors for novel therapeutics. Trends Mol. Med. 11 (2005) 104-113
30. Tsai J.H., and Lee W.M. Modeling antiangiogenesis gene therapy. Cancer Biol. Ther. 1 (2002) 554-555
31. Wu H.P., Feng G.S., Liang H.M., Zheng C.S., and Li X. Vascular endothelial growth factor antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats. World J. Gastroenterol. 10 (2004) 813-818
32. Namiecinska M., Marciniak K., and Nowak J.Z. VEGF as an angiogenic, neurotrophic, and neuroprotective factor. Postepy Hig. Med. Dosw. (Online) 59 (2005) 573-583
33. Tao J., Tu Y.T., and Huang C.Z. Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach. Br. J. Dermatol. 153 (2005) 715-724
34. Rhee J., and Hoff P.M. Angiogenesis inhibitors in the treatment of cancer. Expert Opin. Pharmacother. 6 (2005) 1701-1711
35. Takei Y., Katomatsu K., and Matsuo S. Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res. 61 (2001) 8486-8491
36. Lu P.L., Xie F.Y., and Woodle M.C. Modulation of angiogenesis with siRNA inhibitors for novel therapeutics. Trends Mol. Med. 11 (2005) 104-113
37. Saito G., Swanson J.A., and Lee K.D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 55 (2003) 199-215
38. Hammond S.M., Caudy A.A., and Hannon G.J. Post-transcriptional gene silencing by double-stranded RNA. Nat. Rev., Genet. 2 (2001) 110-119
39. Hammond S.M., Bernstein E., Beach D., and Hannon G.J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404 (2000) 293-296
40. Zhang W., Jiang X., He Z., Xiong D., Zheong P., An Y., and Shi L. Thermoresponsive core-shell-corona micelles of poly(ethyleneglycol)-b-poly(N-isopropylacrylamide)-b-polystyrene. Polymer 47 (2006) 8203-8209
41. Lee S.H., Kim S.H., and Park T.G. Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide. Biochem. Biophys. Res. Comm. 357 (2007) 511-516
42. Schlee M., Hornung V., and Hartmann G. siRNA and isRNA: two edges of one sword. Mol. Ther. 14 (2006) 463-470
43. Wu W.Z., Sun H.C., Shen Y.F., Chen J., Wang L., Tang Z.Y., Lliakis G., and Liu K.D. Interferon alpha 2a downregulates VEGF expression through P13 kinase and MAP kinase signaling pathways. J. Cancer Res. Clin. Oncol. 131 (2005) 169-178
44. Sledz C.A., Holko M., de Veer M.J., Silverman R.H., and Williams B.R.G. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5 (2003) 834-839
45. Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., and MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23 (2005) 457-462
46. Judge A.D., Bola G., Lee G., and MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13 (2006) 494-505
47. Bijsterbosch M.K., Manoharan M., and Rump E.T. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res. 25 (1997) 3290-3296
48. van de Water F.M., Boerman O.C., Wouterse A.C., Peter J.G., Russel F.G., and Masereeuw R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab. Dispos. 34 (2006) 1393-1397
49. Braasch D.A., Paroo Z., and Constantinescu A. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett. 14 (2004) 1139-1143
50. Fee C.J. Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules. Biotechnol. Bioeng. 98 (2007) 725-731
51. Meng F., Engbers G.H., and Feijen J. Polyethylene glycol-grafted polystyrene particles. J. Biomed. Mater. Res. 70A (2004) 49-58
52. Macrae I.J., Zhou K., Li F., Repic A., Brooks A.N., Cande W.Z., Adams P.D., and Doudna J.A. Structural basis for double-stranded RNA processing by Dicer. Science 311 (2006) 195-198
53. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284